|
Written by Lauren Rhone
|
|
Thursday, 01 March 2007 |
|
Source: Advanced Life Sciences
http://www.advancedlifesciences.com/portfolio/icd.htm
CETHROMYCIN We have an exclusive worldwide license (excluding Japan) from Abbott Laboratories to develop and commercialize cethromycin. Cethromycin is a novel ketolide antibiotic in Phase III clinical development for the treatment of community acquired pneumonia and other respiratory tract infections. The total worldwide market for antibiotics in 2003 was approximately $25 billion. Ketolides, a new class of antibiotics that treat respiratory tract infections, have demonstrated strong activity against resistant pathogens such as Streptococcus pneumoniae.In vitro, cethromycin has been shown to be active against upper and lower respiratory tract pathogens, including penicillin- and macrolide-resistant Gram-positive bacteria. Cethromycin has been tested in approximately 3,800 human subjects during clinical trials to date. Abbott Laboratories completed six Phase III clinical trials to determine safety and efficacy of the compound in the treatment of community acquired pneumonia, bronchitis, pharyngitis and sinusitis.We believe that cethromycin, if approved, would build upon the growing market acceptance of ketolide compounds in the antibiotic marketplace and prove to be an attractive treatment for community acquired pneumonia and other respiratory tract infections.
Source: Advanced Life Sciences
http://www.advancedlifesciences.com/portfolio/icd.htm
|
|
Last Updated ( Friday, 02 March 2007 )
|
|
|
Written by Lauren Rhone
|
|
Thursday, 01 March 2007 |
|
By Neil Osterweil, Senior Associate Editor, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
February 28, 2007
SAN DIEGO, Feb. 28 -- Allergic fungal sinusitis deserves a place of its own at the table of nasty chronic rhinosinusitis infections, researchers asserted here.
It may account for up to 10% of chronic rhinosinusitis, said Patricia S. Hutcheson, of Saint Louis University Medical School, at a briefing during the American Academy of Allergy, Asthma, & Immunology meeting here.
"Allergic fungal sinusitis appears to be a separate and distinct form of chronic rhinosinusitis," she said.
"Allergic fungal sinusitis appears to be a separate and distinct form of chronic rhinosinusitis," she said.
Clinically, patients with allergic fungal sinusitis look pretty much the same as those with chronic rhinosinusitis of non-fungal origin, but the serology tells a different story, said Raymond G. Slavin, M.D., director of the division of allergy & immunology, at Saint Louis University, who headed the research team.
The question is, however, what can be done about it?
|
|
Last Updated ( Friday, 02 March 2007 )
|
|
Read more...
|
|
|
Written by Lauren Rhone
|
|
Wednesday, 25 October 2006 |
|
25 Sep 2006
Researchers at Johns Hopkins have evidence that curbed activity from several key chemicals on the inner lining of the nose are linked to chronic sinusitis that fails to respond to the usual current treatments.
An estimated 32 million Americans know the misery of persistent inflammation of the moist tissue that lines the nose and sinus cavities. The result is clogged passages and recurring infections, according to the U.S. Centers for Disease Control and Prevention.
Because nearly one in 10 of those treated see symptoms return within weeks or months after drugs or surgery fail to keep the sinus passages open, scientists have long suspected that these resistant cases had some underlying problem with the immune system contributing to the ailment.
|
|
Last Updated ( Thursday, 26 October 2006 )
|
|
Read more...
|
|
|
|
<< Start < Prev 1 2 Next > End >>
|
| Results 1 - 4 of 6 |
